MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.98
-0.19 (-0.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close19.17
Open19.25
Bid19.02 x 800
Ask19.10 x 4000
Day's Range18.92 - 19.48
52 Week Range18.92 - 42.50
Volume5,052,496
Avg. Volume7,362,411
Market Cap9.783B
Beta (3Y Monthly)1.59
PE Ratio (TTM)41.26
EPS (TTM)0.46
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est31.56
  • There's misinformation out there on generic drugs: Association of Accessible Medicines CEO
    CNBC Videos12 days ago

    There's misinformation out there on generic drugs: Association of Accessible Medicines CEO

    CNBC's "Power Lunch" team discusses generic drug makers' price fixing allegations with Chester "Chip" Davis, CEO of the Association of Accessible Medicines.

  • Teva, 19 other drug companies accused of inflating drug prices
    Yahoo Finance Video13 days ago

    Teva, 19 other drug companies accused of inflating drug prices

    Pharmaceutical company Teva is accused of inflating drug prices. The stock plummeting after 44 states accused Teva and 19 other drug companies of driving up the market prices for generic drugs to avoid competition. Yahoo Finance's Seana Smith and Jared Blikre discuss.

  • Forty-four states accuse Teva Pharmaceutical of inflating drug prices
    CNBC Videos13 days ago

    Forty-four states accuse Teva Pharmaceutical of inflating drug prices

    Forty-four U.S. states, led by Connecticut Attorney General William Tong, claim that 20 drug companies, including Teva USA, "systematically" divided up the market for generic drugs to avoid competing with one another, according to 500-page lawsuit filed late Friday in the U.S. District Court in Connecticut.

  • An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars
    Investor's Business Daily2 days ago

    An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars

    Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.

  • Amgen (AMGN) Offers to Acquire Drug Discovery Platform
    Zacks3 days ago

    Amgen (AMGN) Offers to Acquire Drug Discovery Platform

    Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

  • PR Newswire6 days ago

    Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas. YUPELRI® (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the U.S.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of MYL earnings conference call or presentation 7-May-19 2:00pm GMT

    Q1 2019 Mylan NV Earnings Call

  • Reuters6 days ago

    South Africa's Aspen sells Australian prescription portfolio to Mylan

    Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million). In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialized in Australia and New Zealand. "The divestment is in line with the group's ongoing portfolio management approach and its stated intention to not only acquire value enhancing products, but to also divest of non-core assets, thereby ensuring enhanced operational focus," Aspen said in a statement.

  • PR Newswire8 days ago

    Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic Society International Conference

    Four posters highlight Mylan's rigorous research and development program HERTFORDSHIRE, England , and PITTSBURGH , May 18, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.  (NASDAQ: MYL) today ...

  • Mylan to Host Investor Day on July 31, 2019 in New York City
    PR Newswire9 days ago

    Mylan to Host Investor Day on July 31, 2019 in New York City

    HERTFORDSHIRE, England and PITTSBURGH, May 17, 2019 /PRNewswire/ -- Mylan N.V. (MYL) yesterday presented at the Bank of America Merrill Lynch Healthcare Conference, where the company announced that it will host an Investor Day on July 31, 2019 in New York City. CEO Heather Bresch and Mylan's senior leadership team will share the company's long-term strategic plan, including a strong focus on sustaining profitable growth. As an incremental overlay to the strategic plan, leaders also will provide additional detail on the company's plans to refine its product portfolio, new product launch priorities, commercial focus and operations configuration resulting from their in-depth review of market economics and trends and Mylan's competitive position.

  • Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?
    Investor's Business Daily10 days ago

    Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?

    The prices of generic drugs across the universe of pharmaceutical companies appeared to stabilize in the first quarter — shucking off years of broad decline, Wall Street analysts say.

  • Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
    PR Newswire11 days ago

    Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

    HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, May 15, 2019 /PRNewswire/ -- Mylan N.V. (MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that final data from the HERITAGE study will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The HERITAGE study compared Ogivri™ to the reference product, Herceptin®, in patients with HER2+ metastatic breast cancer in combination with taxanes for the first 24 weeks and then as a monotherapy until progression.

  • Teva Hits Fibonacci Support on Concerns Over Lawsuit
    Investopedia11 days ago

    Teva Hits Fibonacci Support on Concerns Over Lawsuit

    Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.

  • Here are the most and least volatile stocks since Trump ramped up trade conflict
    MarketWatch11 days ago

    Here are the most and least volatile stocks since Trump ramped up trade conflict

    DEEP DIVE A return to stock-market volatility no doubt has many investors worried. We have seen that over long periods, low-volatility index funds have performed better than their full-index benchmarks.

  • MarketWatch11 days ago

    Mylan's stock falls toward 7 1/2-year low; credit rating now in danger of downgrade to 'junk' at Fitch

    Shares of Mylan N.V. sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status. Mylan's long-term issuer default rating at Fitch is BBB-, the lowest investment-grade rating. Fitch said the revised outlook reflects its expectation that gross leverage may remain elevated over the near term because of slower-than-expected revenue growth, cash generation and debt reduction. Fitch's rating and outlook is similar to S&P Global Ratings' BBB- rating with a negative outlook, while Moody's Investors Service has a Baa3 rating--one notch above "junk"--with a stable outlook. Generic drug maker stocks have been under pressure in recent weeks, and took another header on Monday after more than 40 state attorneys general filed suit against 20 makers of generic medications, alleging a conspiracy to artificially inflate prices and reduce competition. Shares of fellow generic drug maker Teva Pharmaceutical Industries Ltd. slid 6.1% in morning trade to a 1 1/2-year low. Year to date, Mylan's stock has tumbled 27.6% and Teva shares have plunged 26.2%, while the SPDR Health Care Select Sector ETF has gained 1.3% and the S&P 500 has tacked on 13.3%.

  • The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

  • AbbVie Settles Humira Litigation With Boehringer Ingelheim
    Zacks11 days ago

    AbbVie Settles Humira Litigation With Boehringer Ingelheim

    AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

  • Here's Why Generic-Drug Manufacturers Were Down Monday
    Motley Fool12 days ago

    Here's Why Generic-Drug Manufacturers Were Down Monday

    Forty-four states have brought a lawsuit against the industry.

  • Generic Drugmakers Face Antitrust Suit Alleging Price Fixing
    Zacks12 days ago

    Generic Drugmakers Face Antitrust Suit Alleging Price Fixing

    Shares of generic drugmakers decline on allegations of price fixing by 44 states.

  • Mylan Reiterates 2019 Revenue Guidance for These Segments
    Market Realist12 days ago

    Mylan Reiterates 2019 Revenue Guidance for These Segments

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidance for Europe and Rest of World In the first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance in the mid-single

  • Barrons.com13 days ago

    The Dow Plunges 617 Points Because China Is Hitting Back With Retaliatory Tariffs

    News of China’s retaliatory tariffs sent shares tumbling. The Dow Jones Industrial Average lost 2.38% to close at 25,324.99. The S&P 500 has dropped 2.41% to finish at 2811.87, and the Nasdaq Composite dropped 3.41% to close at 7647.02.

  • Mylan Call Options Hot as Stock Hits New Low
    Schaeffer's Investment Research13 days ago

    Mylan Call Options Hot as Stock Hits New Low

    One trader bet $1.4 million on a quick bounce for the EpiPen maker

  • Barrons.com13 days ago

    2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

    Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.

  • Mylan Reiterated 2019 Revenue Growth Guidance for North America
    Market Realist13 days ago

    Mylan Reiterated 2019 Revenue Growth Guidance for North America

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)North America revenue growth trendsDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance of high-single-digits for its